SCHEMBL13197837

SCHEMBL13197837

CC(CO)NC(=O)c1nc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cn1Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.48
FPR2 P25090 1/20 0.47
TP53 P04637 1/20 0.45
IGF1R P08069 2/20 0.44
EPHX2 P34913 5/20 0.44
PPARA Q07869 2/20 0.44
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.44
RECQL P46063 1/20 0.44
AHR P35869 1/20 0.42
LMNA P02545 1/20 0.42
CACNA1G O43497 1/20 0.42
CACNA1H O95180 1/20 0.42
CACNA1I Q9P0X4 1/20 0.42
P2RY1 P47900 2/20 0.41
SERPINE1 P05121 2/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13197822 0.88 EPHX2 (0.43) SMN1; SMN2FPR2IGF1REPHX2PPARA
SCHEMBL13197831 0.86 EPHX2 (0.42) FPR2IGF1REPHX2ALDH1A1AHR
SCHEMBL2567978 0.86 EPHX2 (0.53) SMN1; SMN2FPR2TP53IGF1REPHX2
SCHEMBL13197853 0.85 EPHX2 (0.43) EPHX2ALDH1A1AHRHPGD
SCHEMBL13197833 0.85 EPHX2 (0.48) SMN1; SMN2FPR2TP53IGF1REPHX2
SCHEMBL13197846 0.85 EPHX2 (0.42) FPR2IGF1REPHX2ALDH1A1AHR
SCHEMBL13197817 0.85 EPHX2 (0.44) EPHX2ALDH1A1AHRHPGD
SCHEMBL13197836 0.84 IGF1R (0.47) SMN1; SMN2FPR2TP53IGF1REPHX2
SCHEMBL13197832 0.82 EPHX2 (0.54) SMN1; SMN2IGF1REPHX2PPARALMNA
SCHEMBL13197917 0.82 MCHR1 (0.48) SMN1; SMN2FPR2TP53IGF1REPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-7767704-B2 Antiviral 4-aminocarbonylamino-substituted imidazole compounds AICURIS GMBH & CO. KG (DE) 2010-08-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds BAYER HEALTHCARE AG (DE) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004275-A1 Antiviral 4-Aminocarbonylamino-Substituted Imidazole Compounds IRF3, EIF2AK2, ZC3HAV1 SMN1; SMN2 2449/4885FPR2 4423/4885TP53 935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.